Download MendeleyDiscovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism.
Ahn, K., Boehm, M., Brown, M.F., Calloway, J., Che, Y., Chen, J., Fennell, K.F., Geoghegan, K.F., Gilbert, A.M., Gutierrez, J.A., Kalgutkar, A.S., Lanba, A., Limberakis, C., Magee, T.V., O'Doherty, I., Oliver, R., Pabst, B., Pandit, J., Parris, K., Pfefferkorn, J.A., Rolph, T.P., Patel, R., Schuff, B., Shanmugasundaram, V., Starr, J.T., Varghese, A.H., Vera, N.B., Vernochet, C., Yan, J.(2016) ACS Chem Biol 11: 2529-2540
- PubMed: 27391855 Search on PubMed
- DOI: https://doi.org/10.1021/acschembio.6b00266
- Primary Citation Related Structures:
5KRE - PubMed Abstract:
Lysophospholipase-like 1 (LYPLAL1) is an uncharacterized metabolic serine hydrolase. Human genome-wide association studies link variants of the gene encoding this enzyme to fat distribution, waist-to-hip ratio, and nonalcoholic fatty liver disease. We describe the discovery of potent and selective covalent small-molecule inhibitors of LYPLAL1 and their use to investigate its role in hepatic metabolism. In hepatocytes, selective inhibition of LYPLAL1 increased glucose production supporting the inference that LYPLAL1 is a significant actor in hepatic metabolism. The results provide an example of how a selective chemical tool can contribute to evaluating a hypothetical target for therapeutic intervention, even in the absence of complete biochemical characterization.
- Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Research Unit, Pfizer Inc. , 610 Main Street, Cambridge, Massachusetts 02139, United States.
Organizational Affiliation:
